inflammasom
engag
inflammatori
respons
acut
lung
injuri
ali
purinerg
receptor
report
upstream
activ
howev
therapeut
implic
ali
remain
explor
present
studi
use
lipopolysaccharid
lp
induc
mous
model
investig
therapeut
potenti
blockag
ali
result
show
inflammasom
pathway
significantli
upregul
lung
ali
mice
compar
control
mice
antagonist
suppress
activ
product
neutrophil
infiltr
product
result
signific
amelior
lung
injuri
moreov
blockag
significantli
inhibit
inflammasom
activ
product
bone
marrow
deriv
macrophag
similar
result
obtain
use
anoth
inhibitor
brilliant
blue
g
bbg
vivo
thu
pharmacolog
blockag
pathway
consid
potenti
therapeut
strategi
patient
ali
acut
lung
injuri
ali
sever
ali
defin
acut
respiratori
distress
syndrom
ard
major
caus
hypoxem
respiratori
failur
adult
hospit
high
morbid
mortal
mani
condit
trauma
infect
sepsi
could
lead
ali
despit
divers
etiolog
inflamm
take
indispens
part
process
ali
although
mani
medic
therapi
use
treat
aliard
still
inhospit
mortal
rate
thu
develop
novel
therapeut
strategi
especi
target
overwhelm
inflamm
ali
remain
urgent
best
character
famili
member
nodlik
receptor
nlr
involv
innat
adapt
immun
respons
compos
inflammasom
intracellular
molecul
inflammatori
caspas
apoptosisassoci
specklik
protein
contain
card
asc
briefli
upon
activ
interact
asc
bridg
procaspas
allow
activ
caspas
activ
caspas
cleav
proform
matur
activ
form
lung
inflammasom
activ
product
augment
lp
challeng
ali
mice
membran
protein
activ
extracellular
atp
act
upstream
inflammasom
mediat
product
lp
administr
increas
express
lung
parenchyma
mice
show
decreas
polymorphonuclear
cell
infiltr
less
inflammatori
cytokin
product
reduc
collagen
deposit
howev
still
unknown
contribut
pathogenesi
ali
studi
demonstr
pharmacolog
blockad
use
select
antagonist
effect
amelior
ali
mice
via
inhibit
inflammasom
pathway
male
mice
purchas
hous
specif
pathogenfre
condit
experiment
anim
center
sun
yatsen
univers
guangzhou
china
experi
approv
ethic
committe
sun
yatsen
univers
mice
kept
pathogenfre
facil
experi
perform
accord
nation
institut
health
guid
care
use
anim
lpsinduc
ali
model
creat
describ
previous
male
mice
week
age
anesthet
intraperiton
intern
immunopharmacolog
ketamin
mgkg
xylazin
mgkg
mgkg
lp
sigmaaldrich
st
loui
mo
usa
deliv
phosphatebuff
salin
pb
lung
via
angiocath
cathet
use
endotrach
tube
anim
roll
side
side
administr
ensur
even
distribut
normal
control
mice
given
intratrach
instil
pb
bmdm
gener
mice
previous
describ
briefli
femora
tibia
flush
cold
rpmi
cell
suspend
rpmi
medium
contain
fetal
calf
serum
hyclon
logan
utah
usa
cell
cultur
humidifi
atmospher
contain
co
ngml
macrophag
coloni
stimul
factor
mcsf
life
technolog
grand
island
ny
usa
ml
cultur
medium
day
medium
chang
everi
day
peconjug
mous
fitcconjug
mous
ebiosci
san
diego
ca
usa
use
confirm
n
puriti
bmdm
flow
cytometr
analysi
bmdm
prime
lp
presenc
absenc
mm
h
follow
stimul
atp
mm
h
follow
differ
intervent
cell
supernat
collect
detect
elisa
r
system
minneapoli
usa
accord
manufactur
instruct
cell
subject
western
blot
analysi
inflammasom
activ
abcam
cambridg
uk
dilut
mgml
salin
previous
describ
mice
treat
intraperiton
mgkg
everi
h
first
inject
began
h
lp
administr
group
mice
sacrif
h
lp
administr
bronchoalveolar
lavag
bal
fluid
collect
cell
count
protein
quantif
enzymelink
immunosorb
assay
elisa
lung
tissu
collect
histolog
immunohistochemistri
elisa
western
blot
analysi
anoth
antagosist
brilliant
blue
g
bbg
sigmaaldrich
st
loui
mo
usa
also
use
studi
bbg
dilut
mgml
vehicl
salin
solut
mice
treat
intraperiton
bbg
mgkg
everi
h
first
inject
began
h
lp
administr
previous
describ
mice
sacrif
h
lp
administr
bronchoalveolar
lavag
bal
perform
previous
describ
briefli
mice
anesthet
sacrif
heart
punctur
open
thorac
caviti
trachea
expos
steril
needl
blunt
end
insert
trachea
small
semiexcis
ml
pb
inject
withdrawn
first
lavag
lavag
procedur
repeat
twice
total
volum
ml
bal
fluid
per
mous
collect
bal
fluid
centrifug
g
min
pellet
cell
supernat
collect
elisa
total
protein
analysi
pellet
cell
resuspend
small
volum
serumfre
dmem
cultur
medium
life
technolog
grand
island
ny
usa
total
cell
count
determin
grid
hemocytomet
differenti
cell
count
enumer
cytospinprepar
slide
stain
wrightgiemsa
stain
total
cell
count
crosssect
per
sampl
number
neutrophil
calcul
total
cell
count
time
percentag
neutrophil
balf
sampl
total
protein
level
determin
use
bca
protein
assay
kit
thermo
fisher
scientif
rockford
il
usa
accord
manufactur
instruct
lung
tissu
bal
fluid
measur
use
elisa
kit
mous
r
system
minneapoli
usa
elisa
readysetgo
kit
mous
ebiosci
san
diego
ca
usa
respect
follow
manufactur
instruct
paraformaldehydefix
paraffinembed
lung
tissu
section
hematoxylin
eosin
stain
immunohistochem
stain
abcam
cambridg
uk
santa
cruz
biotechnolog
dalla
texa
usa
section
counterstain
hematoxylin
number
cell
lung
count
consecut
field
high
power
field
hpf
express
cellshpf
protein
lung
tissu
extract
cell
lysi
buffer
cell
signal
technolog
beverli
usa
analyz
western
blot
describ
previous
primari
antibodi
use
studi
includ
mous
adipogen
san
diego
ca
usa
rabbit
antibodi
abcam
cambridg
uk
mous
adipogen
rabbit
antiasc
adipogen
antigapdh
antibodi
santa
cruz
biotechnolog
hrp
conjug
antimous
antirabbit
igg
cell
signal
technolog
use
secondari
antibodi
signal
detect
enhanc
chemiluminesc
cell
signal
technolog
data
present
mean
sem
statist
analys
perform
use
oneway
anova
data
analyz
use
spss
softwar
version
p
valu
less
consid
signific
express
inflammasom
pathway
examin
mous
model
lpsinduc
lung
injuri
enhanc
protein
express
asc
observ
lung
lpsinduc
lung
injuri
mice
compar
control
mice
treat
pb
fig
activ
caspas
subunit
repres
highli
activ
tetramer
form
process
caspas
express
subunit
caspas
significantli
elev
lung
lpsinduc
lung
injuri
mice
compar
normal
control
mice
fig
effect
select
inhibitor
activ
inflammasom
test
express
asc
caspas
lung
tissu
significantli
downregul
treatment
demonstr
western
blot
analysi
fig
howev
express
precursor
form
activ
influenc
effect
lung
injuri
induc
lp
investig
histolog
examin
h
e
stain
immunohistochem
stain
shown
fig
inflammatori
cell
infiltr
observ
pulmonari
interstitium
lpsinduc
lung
injuri
mice
significantli
reduc
treatment
addit
larg
number
macrophag
also
detect
lpsinduc
injur
lung
significantli
reduc
treatment
fig
c
investig
effect
lung
inflamm
bal
fluid
collect
cell
count
fig
c
wrightgiemsa
stain
fig
total
protein
analysi
fig
normal
control
mice
cell
observ
bal
fluid
almost
alveolar
macrophag
howev
cell
neutrophil
observ
bla
fluid
lpsinduc
lung
injuri
mice
contrast
significantli
reduc
neutrophil
total
cell
number
coincid
cell
count
total
protein
level
also
elev
lpsinduc
lung
injuri
group
significantli
reduc
treatment
fig
import
downstream
molecular
modul
inflammasom
pathway
act
pivot
inflammatori
factor
lpsinduc
lung
injuri
express
lung
tissu
bal
fluid
appar
enhanc
lpsinduc
lung
injuri
mice
compar
normal
control
select
inhibitor
significantli
inhibit
product
measur
elisa
fig
c
similar
result
confirm
immunohistochemistri
stain
lung
section
shown
fig
reduc
level
level
lung
tissu
bal
fluid
also
examin
elisa
studi
concentr
remark
enhanc
lung
tissu
bal
fluid
lpsinduc
lung
injuri
mice
compar
normal
control
mice
furthermor
treatment
significantli
suppress
fig
fig
e
express
consid
antiinflammatori
cytokin
also
remark
upregul
lung
tissu
bal
fluid
ali
mice
howev
level
alter
treatment
fig
f
vitro
bone
marrow
deriv
macrophag
use
test
inhibitori
effect
fig
express
asc
activ
caspas
evidenc
increas
well
product
enhanc
treatment
lp
atp
enhanc
express
asc
activ
caspas
well
product
significantli
inhibit
contrast
express
precursor
form
activ
influenc
confirm
vivo
effect
blockag
mediat
inhibit
pathway
treat
ali
mice
anoth
select
inhibitor
bbg
similar
inhibitori
effect
inflammasom
activ
product
observ
shown
fig
inhibit
pathway
result
reduct
inflamm
fig
macrophag
infiltr
fig
lung
ali
mice
total
cell
count
fig
protein
level
fig
bal
fluid
also
significantli
reduc
bbg
treatment
inflamm
hallmark
develop
ali
howev
initi
modif
critic
process
still
beyond
clear
interpret
lpsinduc
lung
injuri
mous
model
use
present
studi
manifest
damag
alveolar
wall
neutrophil
accumul
releas
inflammatori
cytokin
studi
show
blockad
effect
amelior
ali
via
inhibit
inflammasom
pathway
express
mani
type
cell
monocyt
macrophag
dendrit
cell
lymphocyt
endotheli
cell
mast
cell
eosinophil
alveolar
type
epitheli
cell
increas
data
show
correl
inflamm
activ
human
macrophag
trigger
releas
null
mice
protect
ali
induc
lp
studi
express
significantli
enhanc
protein
level
lung
tissu
ali
mice
parallel
alveolar
damag
inflammatori
cytokin
product
dissect
function
role
ali
select
antagonist
use
treat
ali
mice
found
blockag
inhibit
activ
inflammasom
pathway
neutrophil
accumul
product
proinflammatori
cytokin
result
reduct
lung
damag
import
mediat
inflammatori
respons
proteolyt
process
activ
caspas
critic
link
brought
light
recent
report
trigger
activ
activ
result
assembl
complex
facilit
caspas
process
releas
proinflammatori
cytokin
previou
studi
shown
caspas
regul
inflammatori
process
mani
lung
diseas
ali
chlamydia
pneumonia
infect
acut
allerg
airway
inflamm
rituximabinduc
interstiti
lung
diseas
rild
late
lung
fibrosi
studi
activ
lung
ali
mice
accompani
enhanc
express
blockad
result
inhibit
activ
suppress
product
attenu
lung
injuri
indic
pathway
involv
pathogenesi
ali
anoth
indispens
proinflammatori
cytokin
produc
thelper
cell
upregul
act
potent
mediat
autoimmun
neutrophil
inflamm
increas
chemokin
product
variou
tissu
recruit
monocyt
neutrophil
site
inflamm
could
regul
cxc
chemokin
gcsf
product
necessari
neutrophil
differenti
activ
recruit
produc
lymphocyt
report
mediat
lung
inflamm
experiment
silicosi
anim
antibodi
neutral
reduc
neutrophil
influx
lung
injuri
also
found
mediat
ali
induc
influenza
viru
studi
markedli
elev
lung
tissu
bal
fluid
ali
mice
demonstr
elisa
analysi
blockad
significantli
reduc
product
well
neutrophil
accumul
conjunct
inhibit
pathway
addit
key
contributor
human
pulmonari
injuri
viralstorm
sar
coronaviru
infect
acut
respiratori
distress
syndrom
ard
data
show
blockad
also
suppress
product
studi
express
inflammasom
compon
upregul
ali
mice
increas
inflammasom
compon
might
simpli
due
increas
popul
innat
immun
cell
lung
tissu
ali
therefor
suppress
express
inflammmasom
compon
treatment
might
reflect
reduc
infiltr
innat
immun
cell
howev
activ
inflammasom
also
significantli
inhibit
treatment
evidenc
reduc
cleavag
caspas
suggest
therapeut
effect
blockag
mediat
inhibit
activ
rather
nonspecif
reduct
inflammatori
infiltr
confirm
vitro
studi
use
bmdm
show
declin
caspas
activ
treatment
antagonist
activ
pathway
propos
requir
two
signal
signal
prime
cytokin
tolllik
receptor
ligand
lp
trigger
synthesi
signal
activ
signal
atp
nigericin
monosodium
urat
act
receptor
studi
bmdm
prime
lp
presenc
absenc
h
follow
stimul
atp
h
surpris
note
inhibit
activ
also
decreas
express
asc
find
suggest
also
unspecifi
effect
prime
inde
recent
studi
shown
treatment
inhibit
phosphoryl
sinc
requir
synthesi
induc
lp
inhibit
erk
upstream
may
reduc
express
conclus
result
studi
identifi
new
target
ali
therapi
data
shown
blockag
signal
effect
amelior
ali
inhibit
inflammasom
activ
therefor
target
signal
pathway
would
potenti
therapeut
strategi
human
ali
